Michael Chen, Ph.D., Co-Founder & CEO of Great Bay Bio, will present at the Bioprocessing Summit 2026.

Michael Chen will showcase Great Bay Bio’s AlfaCell platform, built on AI and site-specific integration technology. The platform delivers high expression titers of 4–16 g/L and completes RCB construction in roughly 1.5 months. Case studies will demonstrate scalability, expression stability, and the integration of AI-based developability assessment to support IND-enabling manufacturing readiness.

Michael Chen will share insights under the title Parallelizing Molecular Discovery and Early CMC: The PCC Prime Foundry Powered by AI-Driven Site-Specific Integration. He will illustrate how Great Bay Bio’s PCC Prime Foundry platform, driven by AI and site-specific integration technology, helps clients develop PCC molecules featuring druggability and high-yield stable cell lines within 8 months, fully enabling efficient and high-quality innovative research and development of new antibody drugs globally.